Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S.-Japan regulatory reform

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed is working with the Commerce Department to prepare the federal government's September/October submission of issues to be addressed by the Regulatory Reform Initiative. Released June 26, the1 U.S. Trade Representative/Japan's first annual report on the initiative represents "solid first steps in solving the current health care crisis in Japan," according to the association. Absent from the report, which lists such planned reforms as increasing the frequency of reimbursement price redesignations, are U.S. industry's concerns with Japanese foreign reference pricing. A Commerce official noted that the topic of reference pricing was excluded from the final report because the U.S. did not want to lend credence to a policy it opposes...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel